// App-Quantinova.ai

4083 : Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • James J. Harding

Principal Investigators

  • Robin Kate Kelley

  • Benjamin R. Tan

  • Emily Iobst

  • Chayma Boussayoud

  • Kerri E. Muenkel

  • Richard K. G. Do

  • Joanne F. Chou

  • Marinela Capanu

  • Carmen Ruiz

  • Mariam Rodriguez Lee

  • John Wilton

  • Renuka V. Iyer

  • Ghassan K. Abou-Alfa

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • University of California, San Francisco, San Francisco, CA

  • Washington University School of Medicine, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Southern California, Los Angeles, CA

  • Roswell Park Cancer Institute, Buffalo, NY

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Sorafenib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT02642913

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved